Le Lézard
Classified in: Health, Science and technology
Subjects: SVY, TRI

Transcenta Announces Updated Clinical Data from Phase I Study of pH-Dependent PD-L1 Antibody MSB2311 to Be Presented at the 2021 ASCO Annual Meeting


SUZHOU, China, May 13, 2021 /PRNewswire/ -- Transcenta Holding Limited (Transcenta), a clinical stage global biotherapeutics company with fully-integrated capabilities in discovery, development and manufacturing of antibody-based therapeutics, today announced that the updated phase I clinical data on the safety and efficacy of MSB2311, a pH-dependent PD-L1 antibody, in Chinese patients with advanced solid tumors and hematological malignancies will be presented as an abstract online publication at the 57th American Society of Clinical Oncology (ASCO) Annual Meeting. The 2021 ASCO Annual Meeting will be held online from June 4th to June 8th EDT.

Online Publication

Title: Updated safety and efficacy of MSB2311 (an Anti-Programmed Death-Ligand 1 Antibody) in Chinese patients with advanced solid tumors and hematological malignancies from a phase I study.

Abstract Number: e14547

First Author: Lin Shen, MD (Beijing Cancer Hospital)

About MSB2311

MSB2311 is an investigational humanized PD-L1 antibody with pH dependent binding property. PD-L1 is involved in inhibiting the immune system's response to fight cancer. MSB2311 blocks the interaction between PD-L1 and PD-1, which reactivates the suppressed or exhausted anti-tumor effector T cell function in the tumor microenvironment. MSB2311 employs engineered IgG1 which lacks FcR binding. In addition, the binding of MSB2311 to PD-L1 results in internalization of MSB2311 and MSB2311 can dissociate from bound PD-L1 in endosome with pH level lower than 5.5. This allows MSB2311 to be recycled to plasma membrane and be reused to bind with PD-L1 on another tumor cell or immune cell. Results from preclinical studies demonstrate that MSB2311 can inhibit tumor growth of PD-L1 expressing tumor cells in syngeneic mouse-model. Two phase 1 studies of MSB2311 have been completed in the US and China. MSB2311 is currently to be tested in phase 2 trial in patients with solid tumors expressing select biomarker in China.

About Transcenta Holding Limited.

Transcenta is a clinical stage global biotherapeutics company that fully integrates antibody-based biotherapeutics discovery, development and manufacturing. Transcenta has established global footprint, with Headquarter and Discovery and Translational Research Center in Suzhou, Process and Product Development Center and Manufacturing Facility in Hangzhou, and Clinical Development Centers in Beijing, Shanghai and Guangzhou in China and in Princeton, US, and External Partnering Center in Boston, US. Transcenta is developing a panel of nine antibody molecules for oncology and selected non-oncology indications including bone and kidney disorders. Upon the latest financing, the company has raised over $342 million from globally prominent investors. For more information, please visit www.transcenta.com.

SOURCE Transcenta Holding Limited


These press releases may also interest you

at 05:05
Sovos, the always-on compliance company, today announced a joint business relationship with the Belgian PwC Firm PwC Business Advisory Services bv/srl (hereinafter: "PwC"), leveraging the companies' complementary tax and advisory service expertise...

at 05:05
The Ministry of Education and Science, along with Palantir , a leading provider of AI systems, have signed an agreement. The main goal is to facilitate qualitative transformations in the field of education and ensure the maximum number of children...

at 05:00
New Oriental Education and Technology Group Inc. (the "Company" or "New Oriental") , a provider of private educational services in China, today announced that it will report its financial results for the third quarter ended February 29, 2024, before...

at 05:00
Altilium, a UK-based clean technology group focused on supporting the transition to net zero, is pleased to announce a groundbreaking partnership with battery materials and technology company Talga Group Ltd, which will see the two companies working...

at 04:44
Friendly Technologies, a global leader in IoT and telecom device management solutions, announces the release of its latest update for the Friendly Unified Device Management platform, introducing groundbreaking features and improvements with a special...

at 04:41
Invoca, the leading revenue execution platform for revenue teams, has won the CX Today Award for 'Best Conversational Intelligence Solution' of 2024. CX Today, the leading international news publication honouring excellence in CX...



News published on and distributed by: